文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新型苯并咪唑类化合物的设计、合成及对接研究及其在代谢综合征治疗中的应用。

Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.

机构信息

Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, Mississippi 38677, USA.

出版信息

J Med Chem. 2010 Feb 11;53(3):1076-85. doi: 10.1021/jm901272d.


DOI:10.1021/jm901272d
PMID:20073471
Abstract

In addition to lowering blood pressure, telmisartan, an angiotensin (AT(1)) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT(1) receptor with a K(i) = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPARgamma activity (29%) and affinity for the AT(1) receptor (K(i) = 2.5 microM).

摘要

除了降低血压,血管紧张素 II 受体阻断剂替米沙坦,最近还被证明具有作为核过氧化物酶体增殖物激活受体 γ(PPARγ)部分激动剂的多效作用。基于这些发现和替米沙坦与罗格列酮在 PPARγ活性位点的对接构象相似,设计并合成了两类苯并咪唑衍生物作为双重 PPARγ激动剂/血管紧张素 II 拮抗剂,用于治疗代谢综合征。双苯并咪唑衍生物 4 对 AT(1)受体具有最佳亲和力,K(i)= 13.4 nM,但没有 PPARγ活性。另一方面,单苯并咪唑衍生物 9 在 PPARγ转录激活测定中显示出最高的活性(69%激活),对 AT(1)受体没有亲和力。对接研究导致了具有双重活性的分子 10 的设计,其对 PPARγ具有中等活性(29%),对 AT(1)受体具有亲和力(K(i)= 2.5 microM)。

相似文献

[1]
Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.

J Med Chem. 2010-2-11

[2]
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

J Med Chem. 2011-5-26

[3]
Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.

Cardiovasc Res. 2006-10-1

[4]
Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.

Eur J Med Chem. 2012-1-17

[5]
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

Bioorg Med Chem Lett. 2012-12-1

[6]
Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.

Bioorg Med Chem. 2012-6-5

[7]
Structural basis for telmisartan-mediated partial activation of PPAR gamma.

Hypertens Res. 2012-2-23

[8]
Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.

J Biomol Struct Dyn. 2016-9-7

[9]
Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.

J Pharmacol Exp Ther. 2014-1-14

[10]
Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.

Eur J Med Chem. 2013-8-19

引用本文的文献

[1]
Synthesis and insight into the structure-activity relationships of 2-phenylbenzimidazoles as prospective anticancer agents.

RSC Adv. 2020-6-1

[2]
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1)-Quinolones with Single Dose Cures.

J Med Chem. 2021-5-27

[3]
Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.

Oncotarget. 2017-4-11

[4]
Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Clin Sci (Lond). 2012-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索